North America Pharmacogenomics Market By Technology (Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others), By Application (Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others), By End User (Hospitals and Clinics, Research Institutions, and Academic Institutes)

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Pharmacogenomics Market, by Application
1.4.2 North America Pharmacogenomics Market, by Application
1.4.3 North America Pharmacogenomics Market, by End User
1.4.4 North America Pharmacogenomics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Pharmacogenomics Market by Technology
3.1.1 North America Sequencing Market by Country
3.1.2 North America Polymerase Chain Reaction Market by Country
3.1.3 North America Electrophoresis Market by Country
3.1.4 North America Mass Spectrometry Market by Country
3.1.5 North America Microarray Market by Country
3.1.6 North America Others Market by Country
Chapter 4. North America Pharmacogenomics Market by Application
4.1.1 North America Oncology Market by Country
4.1.2 North America Psychiatry Market by Country
4.1.3 North America Infectious Diseases Market by Country
4.1.4 North America Neurological Diseases Market by Country
4.1.5 North America Pain Management Market by Country
4.1.6 North America Cardiovascular Diseases Market by Country
4.1.7 North America Others Market by Country
Chapter 5. North America Pharmacogenomics Market by End User
5.1.1 North America Hospitals and Clinics Market by Country
5.1.2 North America Research Institutions Market by Country
5.1.3 North America Academic Institutes Market by Country
Chapter 6. North America Pharmacogenomics Market by Country
6.1 USA Pharmacogenomics Market
6.1.1 USA Pharmacogenomics Market by Technology
6.1.2 USA Pharmacogenomics Market by Application
6.1.3 USA Pharmacogenomics Market by End User
6.2 Canada Pharmacogenomics Market
6.2.1 Canada Pharmacogenomics Market by Technology
6.2.2 Canada Pharmacogenomics Market by Application
6.2.3 Canada Pharmacogenomics Market by End User
6.3 Mexico Pharmacogenomics Market
6.3.1 Mexico Pharmacogenomics Market by Technology
6.3.2 Mexico Pharmacogenomics Market by Application
6.3.3 Mexico Pharmacogenomics Market by End User
6.4 Rest of North America Pharmacogenomics Market
6.4.1 Rest of North America Pharmacogenomics Market by Technology
6.4.2 Rest of North America Pharmacogenomics Market by Application
6.4.3 Rest of North America Pharmacogenomics Market by End User
Chapter 7. Company Profiles
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis